Autoimmune disease, Systemic lupus erythematosus
CGEMCullinan ManagementCatalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for CLN-978 (CD19xCD3) in Autoimmune disease, Systemic lupus erythematosus. The expected timing is based on the latest available company guidance and may change.
06/06/26:- EULAR Ph1 poster showed hSLEDAI responses and remissions. Review SLE data at Immunology Day June 10, 2026. 06/10/26:- OUTRACE SLE multi-dose safety favorable; nephritis signals noted. Additional multi-dose data expected Q4 2026; Phase 2a early 2027. 08/06/26:- OUTRACE SLE Ph1 data planned Q4 2026; Phase 2 expansion early 2027.
Verification
Confirm timing and program details against the company announcement or filing.